Stock AVXL ANAVEX LIFE SCIENCES CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Anavex Life Sciences Corp.

Equities

AVXL

US0327973006

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
3.44 USD +1.47% Intraday chart for Anavex Life Sciences Corp. -8.99% -63.05%
Mar. 18 Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia CI
Feb. 07 Transcript : Anavex Life Sciences Corp., Q1 2024 Earnings Call, Feb 07, 2024

Valuation

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 166.4 273.9 1,359 804.4 536.8 282.5 -
Enterprise Value (EV) 1 166.4 273.9 1,359 804.4 536.8 282.5 282.5
P/E ratio -5.85 x -10.1 x -33.2 x -16.6 x -10.9 x -6.04 x -3.95 x
Yield - - - - - - -
Capitalization / Revenue - - - - - - -
EV / Revenue - - - - - - -
EV / EBITDA - - - -15,776,344 x -9,627,301 x - -
EV / FCF - - - -33,186,505 x -19,319,050 x - -
FCF Yield - - - -0% -0% - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 52,651 60,191 75,727 77,943 81,951 82,113 -
Reference price 2 3.160 4.550 17.95 10.32 6.550 3.440 3.440
Announcement Date 12/16/19 12/28/20 11/24/21 11/28/22 11/27/23 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025
Net sales 1 - - - - - - -
EBITDA - - - -50.99 -55.76 - -
EBIT 1 - -31.09 -42 -50.99 -55.76 -52.79 -75
Operating Margin - - - - - - -
Earnings before Tax (EBT) 1 - -26.26 -37.64 -47.62 -47.5 -46.54 -72
Net income 1 - -26.28 -37.91 -47.98 -47.5 -46.62 -72
Net margin - - - - - - -
EPS 2 -0.5400 -0.4500 -0.5400 -0.6200 -0.6000 -0.5700 -0.8700
Free Cash Flow - - - -24.24 -27.78 - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 12/16/19 12/28/20 11/24/21 11/28/22 11/27/23 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - - -
EBITDA - - - - - - - - - - - - -
EBIT 1 -12.25 -11.72 -11.52 -12.46 -15.28 -15.38 -14.19 -13.53 -12.65 - -12 -13.5 -16
Operating Margin - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -11.58 -10.85 -10.41 -12.28 -14.08 -12.99 -13.06 -11.24 -10.21 - -10.6 -12.4 -15
Net income 1 -11.72 -10.88 -10.44 -12.37 -14.29 -12.97 -13.11 -11.28 -10.15 - -10.6 -12.4 -15
Net margin - - - - - - - - - - - - -
EPS 2 -0.1500 -0.1400 -0.1400 -0.1600 -0.1800 -0.1700 -0.1700 -0.1400 -0.1200 -0.1100 -0.1300 -0.1500 -0.1800
Dividend per Share - - - - - - - - - - - - -
Announcement Date 11/24/21 2/9/22 5/10/22 8/9/22 11/28/22 2/7/23 5/9/23 8/8/23 11/27/23 2/7/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2020 2021 2022 2023 2024 2025
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - -24.2 -27.8 - -
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 12/28/20 11/24/21 11/28/22 11/27/23 - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.44 USD
Average target price
40 USD
Spread / Average Target
+1,062.79%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ANAVEX LIFE SCIENCES CORP. Stock Anavex Life Sciences Corp.
-63.05% 282M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. AVXL Stock
  4. Financials Anavex Life Sciences Corp.